ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA grants Orphan Drug Designation to Epidermolysis Bullosa treatment
December 10, 2019The US Food and Drug Administration has awarded APR-TD011 Orphan Drug Designation, for the treatment of a rare disease. -
Green light for Amryt's epidermolysis bullosa study
January 08, 2019An Independent Data Monitoring Committee (IDCM) has recommended that Amryt’s pivotal Phase III EASE trial for AP101 - a potential treatment for the currently incurable Epidermolysis Bullosa (EB) - should continue. -
Amryt in-licenses novel gene therapy platform from UCD
July 23, 2018UK biotech Amryt has secured itself access to a novel gene therapy platform that could give rise to a new treatment option for patients with Epidermolysis bullosa (EB), a group of rare inherited skin disorders that cause the skin to become very fragile.
Pharma Sources Insight January 2025
